Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 10.39%.

  • Tarsus Pharmaceuticals' EBITDA Margin rose 372000.0% to 10.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.18%, marking a year-over-year increase of 811900.0%. This contributed to the annual value of 63.06% for FY2024, which is 7154200.0% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' EBITDA Margin stood at 10.39%, which was up 372000.0% from 19.86% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year EBITDA Margin high stood at 31.04% for Q1 2021, and its period low was 4393.79% during Q4 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' EBITDA Margin averaged around 778.46%, with its median value being 81.84% (2024).
  • Within the past 5 years, the most significant YoY rise in Tarsus Pharmaceuticals' EBITDA Margin was 42571600bps (2022), while the steepest drop was -37857700bps (2022).
  • Over the past 5 years, Tarsus Pharmaceuticals' EBITDA Margin (Quarter) stood at 4393.79% in 2021, then skyrocketed by 97bps to 136.63% in 2022, then plummeted by -135bps to 320.4% in 2023, then soared by 89bps to 35.06% in 2024, then soared by 70bps to 10.39% in 2025.
  • Its last three reported values are 10.39% in Q3 2025, 19.86% for Q2 2025, and 32.19% during Q1 2025.